SXTP 60 DEGREES PHARMACEUTICALS I revenue, earnings and financials
For the quarter ended June 30, 2026, 60 DEGREES PHARMACEUTICALS I reported revenue of $208K (up 106.0% from a year earlier), net income of −$2.26M and diluted EPS of −$0.90; over the last four quarters revenue was $1.11M and net income −$8.11M; for the fiscal year ended December 2025 revenue was $1.01M, up 65.5% on the year before.
SXTP annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $1.01M, gross profit $224K, operating income −$7.76M, net income −$7.37M (margin -732.5%), EPS −$11.73
- Fiscal year ended Dec 2024: revenue $608K, gross profit $223K, operating income −$9.72M, net income −$7.95M (margin -1308.0%), EPS −$74.17
- Fiscal year ended Dec 2023: revenue $254K, gross profit −$221K, operating income −$5.15M, net income −$3.77M (margin -1485.1%), EPS −$59.18
- Fiscal year ended Dec 2022: revenue $223K, gross profit −$209K, operating income −$1.75M, net income −$6.18M (margin -2769.5%), EPS −$2.61
SXTP quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $208K (up 106.0% year over year), net income −$2.26M, EPS −$0.90
- Quarter ended Mar 31, 2026: revenue $162K (down 0.9% year over year), net income −$2.09M, EPS −$1.28
- Quarter ended Dec 31, 2025 (from the annual report): revenue $303K (up 25.6% year over year), net income −$1.44M, EPS $0.19
- Quarter ended Sep 30, 2025: revenue $438K (up 223.4% year over year), net income −$2.32M, EPS −$0.66
- Quarter ended Jun 30, 2025: revenue $101K (down 19.2% year over year), net income −$1.73M, EPS −$5.01
- Quarter ended Mar 31, 2025: revenue $164K (up 54.8% year over year), net income −$1.88M, EPS −$6.25
- Quarter ended Dec 31, 2024 (from the annual report): revenue $242K (up 92.3% year over year), net income −$2.05M, EPS −$51.96
- Quarter ended Sep 30, 2024: revenue $135K (up 164.3% year over year), net income −$2.16M, EPS −$2.92
- Quarter ended Jun 30, 2024: revenue $125K (up 109.9% year over year), net income −$4.17M, EPS −$21.12
- Quarter ended Mar 31, 2024: revenue $106K (up 515.4% year over year), net income $430K, EPS $1.83
- Quarter ended Dec 31, 2023 (from the annual report): revenue $126K, net income −$2.01M, EPS −$50.34
- Quarter ended Sep 30, 2023: revenue $51.2K (down 69.6% year over year), net income $4.18M, EPS $9.13
- Quarter ended Jun 30, 2023: revenue $59.5K (up 31.8% year over year), net income −$3.34M, EPS −$16.84
- Quarter ended Mar 31, 2023: revenue $17.2K, net income −$2.60M, EPS −$1.13
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$1.68M, EPS n/a
- Quarter ended Sep 30, 2022: revenue $168K, net income −$1.45M, EPS −$0.61
- Quarter ended Jun 30, 2022: revenue $45.2K, net income −$2.15M, EPS −$0.96
- Quarter ended Mar 31, 2022: revenue n/a, net income −$907K, EPS n/a
SXTP cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$6.85M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$5.65M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$4.54M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$1.01M, share buybacks n/a
SXTP balance sheet
- Jun 30, 2026: cash $1.02M, total assets $4.28M, total liabilities $1.75M, shareholders' equity $2.61M
- Mar 31, 2026: cash $3.34M, total assets $6.76M, total liabilities $2.02M, shareholders' equity $4.83M
- Dec 31, 2025: cash $1.51M, total assets $5.37M, total liabilities $1.99M, shareholders' equity $3.46M, long-term debt $144K
- Sep 30, 2025: cash $4.12M, total assets $6.69M, total liabilities $2.34M, shareholders' equity $4.43M
- Jun 30, 2025: cash $1.97M, total assets $4.18M, total liabilities $1.84M, shareholders' equity $2.43M
- Mar 31, 2025: cash $3.45M, total assets $5.98M, total liabilities $1.95M, shareholders' equity $4.11M
- Dec 31, 2024: cash $1.66M, total assets $5.76M, total liabilities $1.80M, shareholders' equity $4.04M, long-term debt $147K
- Sep 30, 2024: cash $3.30M, total assets $7.42M, total liabilities $1.46M, shareholders' equity $6.04M
What is SXTP's revenue?
60 DEGREES PHARMACEUTICALS I reported $1.11M of revenue over its last four quarters, through June 30, 2026.
Is SXTP profitable?
No. 60 DEGREES PHARMACEUTICALS I lost $8.11M over the last four quarters.
What is SXTP's EPS?
Diluted earnings per share over the last four quarters were −$2.65; −$0.90 in the latest quarter.